eHIV Review

Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV

In this issue:

In this issue of eHIV Review, Kara Wegermann MD, Assistant Professor of Medicine at Duke University School of Medicine, reviews emerging data across the metabolic dysfunction-associated steatotic liver disease (MASLD) care continuum, from real-world gaps in screening and fibrosis staging to the evolving therapeutic landscape. Dr. Wegermann highlights the limitations of conventional screening approaches in people living with HIV, discusses the impact of diet and exercise interventions, and examines how the first FDA-approved therapies for MASH and GLP‑1 receptor agonists like semaglutide may (or may not yet) translate to people living with HIV.  

Learning objective:

Appraise efficacy of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) for people living with HIV.